Jump to content

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. (Q40014063)

From Wikidata
scientific article published on 11 February 2008
edit
Language Label Description Also known as
default for all languages
No label defined
    English
    Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    scientific article published on 11 February 2008

      Statements

      Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. (English)

      Identifiers

       
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      edit